NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2019
CVR: 24257924
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2019. In 2019, the company reported a net result of DKK 3,722,000 compared with DKK -1,984,000 the year before. Equity in the 2019 report amounted to DKK 15,569,000. The solvency ratio was 99.8%.
- Profit/Loss
- DKK 3,722,000
- Equity
- DKK 15,569,000
- Total Assets
- DKK 15,602,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | - | 3.7M | 15.6M | - |
| 2018 | - | - | -2M | 11.8M | - |
| 2017 | - | - | -2.3M | 13.8M | - |
| 2016 | - | - | 1.7M | 16.1M | - |
| 2015 | - | - | 1.9M | 14.4M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2018. The net result was DKK -1,984,000.
About NOVO NORDISK PHARMACEUTICALS A/S
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
